Antoine Italiano

Antoine Italiano is a French oncologist who leads early-phase trial development for rare solid tumors including sarcomas, and has made contributions to identifying molecularly defined subsets within sarcoma histotypes amenable to targeted therapy. He contributed to development of tazemetostat in INI1-negative epithelioid sarcoma, demonstrating EZH2 inhibition activity in SWI/SNF-mutant tumors. Italiano has been a leader in UNICANCER early phase trial design for rare cancers and has investigated ALK inhibitors in inflammatory myofibroblastic tumor, MEK inhibitors in NF1-related MPNST, and other precision oncology approaches in rare sarcoma subsets.